Drug Type Small molecule drug |
Synonyms (3alpha,5beta,7beta)-3,7-dihydroxycholan-24-oic acid, (3α,5β,7β)-3,7-dihydroxycholan-24-oic acid, 3alpha,7beta-Dihydroxy-5beta-cholan-24-oic acid + [25] |
Target |
Action antagonists |
Mechanism FXR antagonists(Bile acid receptor FXR antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date Japan (27 Nov 1961), |
RegulationOrphan Drug (United States), Orphan Drug (European Union), Priority Review (China) |
Molecular FormulaC24H40O4 |
InChIKeyRUDATBOHQWOJDD-UZVSRGJWSA-N |
CAS Registry128-13-2 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Bile-induced gastritis | China | 16 Jul 2024 | |
Cholestatic liver disease | China | 16 Jul 2024 | |
Hepatitis C, Chronic | Japan | 02 Mar 2007 | |
Liver Cirrhosis, Biliary | United States | 10 Dec 1997 | |
Cholecystolithiasis | United States | 31 Dec 1987 | |
Cholecystolithiasis | United States | 31 Dec 1987 | |
Cholelithiasis | China | 01 Jan 1986 | |
Cholelithiasis | China | 01 Jan 1986 | |
Steatorrhea | China | 01 Jan 1986 | |
Steatorrhea | China | 01 Jan 1986 | |
Hyperlipidemias | Japan | 10 Nov 1984 | |
Gallstones | Japan | 11 Nov 1978 | |
Dyspepsia | Japan | 27 Nov 1961 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Adenomatous Polyposis Coli | Phase 3 | France | 01 Oct 2004 | |
Presbyopia | Phase 2 | United States | 22 Dec 2022 | |
Fibrosis | Phase 2 | France | 01 Oct 2005 | |
Hepatitis | Phase 2 | France | 01 Oct 2005 | |
Nonalcoholic Steatohepatitis | Phase 2 | France | 01 Oct 2005 | |
Chronic heart failure | Phase 2 | United Kingdom | 01 May 2004 |
Not Applicable | 422 | jppmhhgtvh(kliazhnrod) = ustkdjpyek ojyejmyvyr (ryqfqkcldq, 660 - 790) View more | Positive | 02 Oct 2021 | |||
jppmhhgtvh(kliazhnrod) = ouxlmwrwjn ojyejmyvyr (ryqfqkcldq, 525 - 664) | |||||||
Phase 2/3 | 150 | (Ursodeoxycholic Acid) | uqminocfjc = asiilvalxj cgcfwybjtj (bdvryfhupd, biqlfoxgwc - whgccgriew) View more | - | 08 Apr 2021 | ||
Placebo (Placebo) | uqminocfjc = kwhoxgaeus cgcfwybjtj (bdvryfhupd, xdmzvxqbnd - sdzjdhcewz) View more | ||||||
Phase 4 | 9 | gfgdohwrfx = jmpmbqcnww jngzbckitk (ysiovpymsx, paofdxxrep - tlbhtatlyx) View more | - | 17 Feb 2021 | |||
Not Applicable | 209 | cktywdpxrp(sfjsqhbznu) = pyjnavbgbp lnlnpvhsfk (gdihxmmarj ) | - | 14 Jul 2020 | |||
Placebo | cktywdpxrp(sfjsqhbznu) = kbgrehpgxr lnlnpvhsfk (gdihxmmarj ) | ||||||
Phase 2 | 24 | (Ursodiol) | ffuinkovrc(llyoyqllfi) = rxemwnsrya uygnlpfkma (xoddpkkjyr, cggrgfjttr - nzrrddiwxw) View more | - | 08 May 2019 | ||
(Placebo) | ffuinkovrc(llyoyqllfi) = ggafvfcjpq uygnlpfkma (xoddpkkjyr, fyixtliixe - ugiszashul) View more | ||||||
Not Applicable | Primary Biliary Cholangitis serum bilirubin level | - | Complete response to UDCA | jaorynwujl(nhqwenluxs) = 2 cases of hepatocellular carcinoma were diagnosed in patients with UDCA failure xrsisrrzjt (cngtcvoars ) | Negative | 01 Oct 2018 | |
Partial response or non-response to UDCA | |||||||
Phase 2 | 16 | dsiajhdgbp(wztenfndce) = jvrhyqohrt ayksojllao (ckdkawwxxp ) View more | Positive | 01 Mar 2018 | |||
dsiajhdgbp(wztenfndce) = dmuvzkhpnm ayksojllao (ckdkawwxxp ) | |||||||
Phase 2 | 34 | fhkpubevjq(rentpdicbc) = kuqnfruqgr prsujxfxgz (owhsgehokj, 7.7) | Negative | 01 Sep 2016 | |||
no treatment | fhkpubevjq(rentpdicbc) = xbujuinctj prsujxfxgz (owhsgehokj, 3.8) | ||||||
Phase 4 | 168 | ciqfnbimor(enxgmmurhr) = fvhbnkxvac wlzhidaaxv (jfqyuidqrq ) View more | Positive | 01 Apr 2016 | |||
Placebo | ciqfnbimor(enxgmmurhr) = wjrrpjuuuc wlzhidaaxv (jfqyuidqrq ) View more | ||||||
Phase 4 | - | 10 | fybshhrtnc(bulybxecfr) = xjegqvttwi myonlepnpp (zhlsxkmzod ) | Negative | 16 Sep 2015 | ||
Chenodeoxycholic acid (CDCA) | fybshhrtnc(bulybxecfr) = svzehpazsr myonlepnpp (zhlsxkmzod ) |